NCT01674725View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C

PHASE3CompletedINTERVENTIONAL

Enrollment

187

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

October 31, 2014

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG

ABT-450/r/ABT-267, ABT-333

Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

DRUG

Ribavirin

Tablet

All Listed Sponsors

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01674725 - A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C | Biotech Hunter | Biotech Hunter